Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma

Απλή σελίδα τεκμηρίου
dc.contributor.authorKaravasilis, V.en
dc.contributor.authorMalamou-Mitsi, V.en
dc.contributor.authorBriasoulis, E.en
dc.contributor.authorTsanou, E.en
dc.contributor.authorKitsou, E.en
dc.contributor.authorPavlidis, N.en
dc.date.accessioned2015-11-24T19:30:13Z
dc.date.available2015-11-24T19:30:13Z
dc.identifier.issn1048-891X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/23045
dc.rightsDefault Licence-
dc.subjectAdenocarcinoma/chemistry/*metabolism/*pathology/therapyen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAntigens, CD34/analysis/*biosynthesisen
dc.subjectAntineoplastic Agents/therapeutic useen
dc.subjectFemaleen
dc.subjectGynecologic Surgical Proceduresen
dc.subjectHumansen
dc.subjectMicrocirculationen
dc.subjectMiddle Ageden
dc.subjectNeoplasm Stagingen
dc.subjectNeovascularization, Pathologic/*physiopathologyen
dc.subjectOvarian Neoplasms/chemistry/*metabolism/*pathology/therapyen
dc.subjectPlatinum Compounds/therapeutic useen
dc.subjectThrombospondin 1/analysis/*biosynthesisen
dc.subjectVascular Endothelial Growth Factor A/analysis/*biosynthesisen
dc.titleClinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinomaen
heal.abstractThe aim of the study was to investigate angiogenesis in patients with advanced-stage ovarian carcinoma. We used paraffin-embedded tumor tissues from 33 patients diagnosed with FIGO III ovarian cancer who had optimal surgery and received platinum-based chemotherapy. The tissue expression of CD34, vascular endothelial growth factor (VEGF), and thrombospondin-1 (TSP-1) was assessed immunohistochemically. CD34 stained hot spot areas were used to evaluate tumor microvessel density (MVD). VEGF and TSP-1 were assessed by semiquantitative methods. The studied molecules were investigated for relationship with standard clinicopathologic parameters. MVD count was high: median value of 39, range 12-143 microvessels/mm2. VEGF was present in all cases and stained strong in 91%. Stroma staining for TSP-1 was weak in 79% of the cases, strong in 6%, and absent in five (15%). We did not find correlations between the three studied markers and histologic type or tumor grade. MVD score did not relate to VEGF or TSP-1. We only observed a trend toward a longer survival in patients with tumors expressing high TSP-1 (60 vs. 36 months, P= 0.1). Proangiogenetic factor VEGF is highly expressed in advanced-stage ovarian carcinomas. The findings of this study may offer support for considering VEGF-targeted therapeutics in ovarian cancer treatment research.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1111/j.1525-1438.2006.00316.x-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16515598-
heal.identifier.secondaryhttp://onlinelibrary.wiley.com/doi/10.1111/j.1525-1438.2006.00316.x/abstract-
heal.journalNameInt J Gynecol Canceren
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2006-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ